• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro

tetano

Editor, Senior Moderator
Nat Commun


. 2025 May 15;16(1):4546.
doi: 10.1038/s41467-025-59870-4. A novel, covalent broad-spectrum inhibitor targeting human coronavirus M[SUP]pro[/SUP]

Jing Sun[SUP] #[/SUP][SUP] 1 2 [/SUP], Deheng Sun[SUP] #[/SUP][SUP] 3 [/SUP], Qi Yang[SUP] #[/SUP][SUP] 1 4 [/SUP], Dong Wang[SUP] #[/SUP][SUP] 1 5 [/SUP], Jingjing Peng[SUP] #[/SUP][SUP] 3 [/SUP], Hu Guo[SUP] #[/SUP][SUP] 1 [/SUP], Xiaoyu Ding[SUP] #[/SUP][SUP] 3 [/SUP], Zhao Chen[SUP] 1 [/SUP], Bin Yuan[SUP] 1 [/SUP], Yan A Ivanenkov[SUP] 6 [/SUP], Jinwei Yuan[SUP] 1 [/SUP], Bogdan A Zagribelnyy[SUP] 7 [/SUP], Yiyun He[SUP] 1 [/SUP], Jingyi Su[SUP] 1 [/SUP], Ling Wang[SUP] 3 [/SUP], Jielin Tang[SUP] 1 4 [/SUP], Zhun Li[SUP] 1 [/SUP], Rong Li[SUP] 8 [/SUP], Taotao Li[SUP] 3 [/SUP], Xiaoyu Hu[SUP] 1 [/SUP], Xing Liang[SUP] 3 [/SUP], Airu Zhu[SUP] 1 [/SUP], Peilan Wei[SUP] 1 [/SUP], Yaya Fan[SUP] 3 [/SUP], Sang Liu[SUP] 3 [/SUP], Jie Zheng[SUP] 1 [/SUP], Xin Guan[SUP] 1 [/SUP], Alex Aliper[SUP] 7 [/SUP], Minglei Yang[SUP] 8 [/SUP], Dmitry S Bezrukov[SUP] 7 [/SUP], Zhanhong Xie[SUP] 1 [/SUP], Victor A Terentiev[SUP] 6 [/SUP], Guilin Peng[SUP] 1 [/SUP], Daniil A Polykovskiy[SUP] 9 [/SUP], Alexander S Malyshev[SUP] 6 [/SUP], Maxim N Malkov[SUP] 7 [/SUP], Qingsong Zhu[SUP] 7 [/SUP], Alán Aspuru-Guzik[SUP] 10 [/SUP], Xiao Ding[SUP] 3 [/SUP], Xin Cai[SUP] 3 [/SUP], Man Zhang[SUP] 3 [/SUP], Jingxian Zhao[SUP] 11 12 13 [/SUP], Nanshan Zhong[SUP] 14 15 [/SUP], Feng Ren[SUP] 16 [/SUP], Xinwen Chen[SUP] 17 [/SUP], Alex Zhavoronkov[SUP] 18 19 [/SUP], Jincun Zhao[SUP] 20 21 22 23 24 [/SUP]



Affiliations
Abstract

Human coronaviruses (CoV) cause respiratory infections that range from mild to severe. CoVs are a large family of viruses with considerable genetic heterogeneity and a multitude of viral types, making preventing and treating these viruses difficult. Comprehensive treatments that inhibit CoV infections fulfill a pressing medical need and may be immensely valuable in managing emerging and endemic CoV infections. As the main protease (M[SUP]pro[/SUP]) is highly conserved across many CoVs, this protease has been identified as a route for broad CoV inhibition. We utilize the advanced generative chemistry platform Chemistry42 for de novo molecular design and obtained novel small-molecule, non-peptide-like inhibitors targeting the SARS-CoV-2 M[SUP]pro[/SUP]. ISM3312 is identified as an irreversible, covalent M[SUP]pro[/SUP] inhibitor from extensive virtual screening and structure-based optimization efforts. ISM3312 exhibits low off-target risk and outstanding antiviral activity against multiple human coronaviruses, including SARS-CoV-2, MERS-CoV, 229E, OC43, NL63, and HKU1 independent of P-glycoprotein (P-gp) inhibition. Furthermore, ISM3312 shows significant inhibitory effects against Nirmatrelvir-resistant M[SUP]pro[/SUP] mutants, suggesting ISM3312 may contribute to reduced viral escape in these settings. Incorporating ISM3312 and Nirmatrelvir into antiviral strategy could improve preparedness and reinforce defenses against future coronavirus threats.


 
Back
Top Bottom